Error message

User warning: The following theme is missing from the file system: WORKING_COPY. For information about how to fix this, see the documentation page. in _drupal_trigger_error_with_delayed_logging() (line 1156 of /home/insysbi8/insysbio.com/docs/includes/bootstrap.inc).

InSysBio to present at PAGE 2019

 

June 5, 2019

InSysBio announces their participation at PAGE 2019 28th Meeting being held from 11 to 14 June 2019 in Stockholm, Sweden. InSysBio is presenting five posters:

Wednesday, June 12 (9:50-11:15):

  • I-86: “Investigation of dose response behavior of bispecific T-cell engaging antibodies using quantitative systems pharmacology modeling” (view abstract) by Oleg Demin Jr and Dmitry Shchelokov

Wednesday, June 12 (15:10-16:40):

  • II-42: “Quantitative Systems Pharmacology model of key intraneuronal pathways regulating toxic protein accumulation” (view abstract) by Mark Meerson, Tatiana Karelina and Diana Сlausznitzer (Abbvie)

Thursday, June 13 (9:55-11:20):

  • III-16: “Physiologically based pharmacokinetic modeling of anti-PD-1 therapeutic antibodies” (view abstract) by Dmitry Shchelokov and Oleg Demin Jr

Thursday, June 13 (15:25-16:50):

  • IV-74: “Amyloid β in vitro prion properties and in vivo pathology exacerbation mechanisms studied by translation quantitative systems pharmacology model for prediction of anti-protofibril immunotherapy effects” (view abstract) by Tatiana Karelina

  • V-89: “Application of different approaches to generate virtual patient populations for QSP model of physiologically based pharmacokinetic model of anti-PD-1 therapeutic antibodies” (view abstract) by Galina Kolesova, Oleg Demin, Evgeny Metelkin and Dmitry Shchelokov

About InSysBio

InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative approach has already become a part of the drug development process implemented by our strategic partners: nowadays there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. The company has published multiple scientific studies in various therapeutic areas. InSysBio team is developing software and tools for QSP and continuously improves methods for biological modeling. For more information about InSysBio, its solutions and services, visit insysbio.com.

Tags: 
UPCOMING EVENT
CONFERENCE